Skip to main content

SJ901 Overview: Insights from the Principal Investigator

Giles Robinson, MD, discusses the rationale for using the MEK inhibitor mirdametinib to target brain tumors in children, adolescents and young adults with low-grade gliomas. 


A Study of MEK Inhibitor Mirdametinib for Low-Grade Glioma


Eligibility for SJ901